Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageOur technology platform, combined with our deep vaccine expertise, is the fuel for innovation and partnerships, and we believe it has the potential to create significant value. Our proprietary Matrix-M™ adjuvant when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Our recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Together, we believe that our technology platform can induce potent, durable and broad immune responses, with the potential to be antigen-sparing.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q1 2026 · $128.2MThe company’s own SEC segment disclosure.
- Licensing Royalties And Other$97.3M76%
- Upfront Fee Amortization$12.1M9%
- Nuvaxovid Sales$9.6M7%
- Milestone Amortization$5.6M4%
- Royalty$3.5M3%
- Support Services$100.0K0%
Novavax, Inc. (NVAX) reported revenue of $140M in Q1 2026 (quarter ended March 31, 2026), down 79% from the same quarter a year earlier. That came with a gross margin of 78% and net loss of $9.5M. For the full year FY2025, revenue was $1.12B (+65% year on year) and net income $440M. Its largest product in 2026-Q1 was Licensing Royalties And Other at $97M, 76% of the disclosed total, just ahead of Upfront Fee Amortization at 9.4%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.